$PFE

HR8032 ensures equitable Medicare payment for cancer treatments, directly benefiting pharmaceutical companies and biotech firms focused on oncology. This bill stabilizes revenue streams for cancer drug manufacturers within the outpatient setting.

The End Veterans Overdose Act of 2026, advancing through the Senate Veterans' Affairs Committee, directs increased funding towards opioid addiction treatment and prevention for veterans. This creates a direct revenue stream for pharmaceutical companies producing addiction treatments and healthcare providers specializing in substance abuse services.

The Veterans SPORT Act, favorably reported by the Committee on Veterans' Affairs, expands access to prosthetics, orthotics, and rehabilitative services for veterans. This bill increases demand for specialized medical devices, rehabilitation facilities, and athletic apparel, directly benefiting companies in these sectors.

The 'Improving Access to Care for Rural Veterans Act' (S3033) advances, indicating increased federal spending on rural veteran healthcare. This bill directly benefits pharmaceutical companies, medical device manufacturers, and healthcare providers with rural presences, as it expands access to care and associated services.

This bill directly targets the availability of mifepristone, a key drug in reproductive healthcare. Its passage would eliminate a significant market for pharmaceutical companies and could increase demand for other healthcare services.

This $19.6 million contract to Advanced Technology International (ATI) for CBRN AVAT_MRNA research is a positive signal for the biotechnology sector, particularly companies involved in mRNA technology, but its direct impact on publicly traded entities is indirect as ATI is a private entity.

This $32.0 million contract to Advanced Technology International for biologic production signals increased government investment in pharmaceutical manufacturing readiness, directly benefiting publicly traded biotechnology and pharmaceutical companies involved in similar advanced material production.

This $304M contract to Advanced Technology International (ATI) for drug substance and product production under the BIOMAP-Consortium is a significant boost for the pharmaceutical manufacturing sector, directly benefiting companies involved in biopharmaceutical production and potentially their equipment suppliers. While ATI is private, this award signals continued government investment in domestic biomanufacturing capabilities, creating a favorable environment for publicly traded pharmaceutical and biotech companies.

This $697 million contract to Phlow Corp. for advanced API manufacturing significantly boosts domestic pharmaceutical supply chain resilience, directly benefiting publicly traded pharmaceutical companies through increased demand for raw materials and manufacturing services. The award aligns with legislative efforts to strengthen healthcare infrastructure and preparedness.

The National Plan for Epilepsy Act (S494) establishes a national strategy for epilepsy research and care. This bill directs federal agencies to coordinate efforts, potentially increasing funding for research and treatment development, benefiting pharmaceutical and biotechnology companies focused on neurological disorders.

The Advancing Education on Biosimilars Act of 2021 increases awareness and adoption of biosimilar drugs, directly benefiting biosimilar manufacturers and increasing competition for branded biologic drug companies. This legislation expands the market for biosimilars and drives down healthcare costs.

The Endless Frontier Act (HR6978) establishes a new directorate within the National Science Foundation (NSF) to fund R&D in critical technology areas, directly benefiting U.S. technology and manufacturing companies. This bill allocates significant federal funds to bolster domestic innovation and competitiveness, creating a direct revenue stream for companies involved in semiconductor manufacturing, artificial intelligence, and biotechnology. The bill's referral to committee indicates initial legislative movement.

The Medical Supply Transparency and Delivery Act mandates increased domestic manufacturing and transparency for medical supplies. This directly benefits U.S. medical manufacturers and logistics companies, creating new revenue streams and strengthening supply chains.

The Pandemic and All-Hazards Preparedness Reauthorization Act of 2013 (S.242) ensures continued funding and strategic direction for public health emergency preparedness. This bill maintains existing support for pharmaceutical companies, medical device manufacturers, and healthcare service providers involved in national health security.

The Pandemic and All-Hazards Preparedness Reauthorization Act of 2013 (PAHPRA) solidified federal funding and strategic direction for public health emergencies. This act directly benefited pharmaceutical and biotechnology companies involved in vaccine and therapeutic development, ensuring sustained government procurement.

The PASTEUR Act aims to create a subscription-style payment model for novel antibiotics, decoupling drug value from sales volume. This bill, if passed, will stabilize the market for antibiotic development, directly benefiting pharmaceutical companies focused on infectious disease research.

The PASTEUR Act establishes a subscription-style payment model for novel antibiotics, guaranteeing revenue for pharmaceutical companies developing new antimicrobial treatments. This de-risks R&D for antibiotics, driving investment and innovation in a critical healthcare area. Companies with strong antibiotic pipelines stand to gain significant, predictable revenue streams.

The Immediate Access for the Terminally Ill Act accelerates patient access to experimental treatments, directly benefiting pharmaceutical and biotechnology companies developing late-stage therapies. This bill expands the market for investigational drugs, increasing revenue potential for companies with promising pipelines.

The Immediate Access for the Terminally Ill Act accelerates patient access to experimental drugs, increasing revenue opportunities for pharmaceutical companies with late-stage clinical pipelines. This bill directly expands the market for investigational therapies by reducing regulatory hurdles.

The motion to reconsider the vote on HR7147 indicates ongoing legislative efforts to finalize consolidated appropriations for FY2026. This procedural step delays the allocation of federal funds across various sectors, creating short-term uncertainty for companies reliant on government contracts and spending. Final passage will release significant capital into the economy.

The Treat and Reduce Obesity Act of 2025 expands Medicare coverage for obesity treatments, directly benefiting pharmaceutical companies producing GLP-1 agonists and medical device manufacturers. This legislation significantly increases the total addressable market for these therapies.

The BUST FENTANYL Act, S860, targets the fentanyl crisis through enhanced detection and interdiction. This bill increases demand for drug screening technologies, laboratory services, and pharmaceutical countermeasures, directly benefiting companies in these sectors.

The 'Skinny Labels, Big Savings Act' directly targets brand-name pharmaceutical companies by limiting their ability to block generic competition. This legislation will reduce drug prices and significantly decrease revenue for innovator drug manufacturers, while benefiting generic drug producers.

The American Innovation and R&D Competitiveness Act of 2025 restores immediate expensing for R&D costs, directly increasing the profitability and investment capacity of R&D-intensive companies. This legislative action provides a significant financial boost to technology, manufacturing, and healthcare sectors.

The Medical Supply Chain Security Act (HR6049) aims to bolster domestic medical supply production and reduce reliance on foreign sources. This will directly benefit U.S.-based medical device and pharmaceutical manufacturers, increasing their market share and contract opportunities. Healthcare providers will also see improved supply stability.

HR4930, by expanding information sharing on intellectual property (IP) violations, directly benefits companies with significant IP portfolios by strengthening enforcement against counterfeiting and piracy. This action increases the value of their intangible assets and reduces revenue loss from illicit trade. Companies like Amazon ($AMZN) and Google ($GOOGL) stand to gain from a more secure digital marketplace.

The PREEMIE Reauthorization Act of 2025 focuses on research and interventions for preterm birth. This bill provides continued, stable funding for existing programs, preventing a lapse in federal support for maternal and infant health initiatives. No new significant market opportunities are created, but existing beneficiaries maintain their revenue streams.

The 'Protecting Free Vaccines Act' aims to maintain free access to vaccines, which directly impacts the revenue models of pharmaceutical companies. This bill, if passed, will likely shift vaccine procurement costs to the federal government, maintaining demand for vaccine manufacturers.

The Access to Pediatric Technologies Act of 2025 (HR1931) will accelerate the development and availability of medical devices and drugs for pediatric use. This creates a new market opportunity for pharmaceutical and medical device companies, driving increased R&D and product launches in the pediatric segment.

This resolution signals a strong legislative intent to reduce the federal budget deficit, which directly translates to cuts in government spending across various sectors. Companies heavily reliant on federal contracts and spending will experience reduced revenue streams. This action will lead to a contraction in government-dependent markets.

The Medicare for All Act, if enacted, eliminates private health insurance and significantly reduces revenue for pharmaceutical and medical device companies. This bill creates a single-payer system, shifting all healthcare spending to the federal government and directly impacting the profitability of current healthcare providers and insurers.

The proposed bill, S4104, establishes a federal database for corporate offenses, increasing regulatory scrutiny and potential penalties for all publicly traded companies. This directly increases compliance costs and legal risks across all sectors, particularly for large corporations with complex operations.